You are here
Medosome Biotec, LLC
UEI: MJJJFTJE1SB5
# of Employees: 1
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
A method for accurate and sensitive detection of HIV drug-resistant minority variants
Amount: $999,999.00PROJECT SUMMARY / ABSTRACT Drug resistance to HIV is a major threat to achieving long-term viral suppression in HIV+ individuals. Up to 16% of newly infected individuals acquire HIV with resistance to ...
STTRPhase II2022Department of Health and Human Services National Institutes of Health -
Next generation quantitative HCV drug resistance assay
Amount: $1,611,097.00PROJECT SUMMARY / ABSTRACT The objective of this Phase II application is to complete the development of a next generation quantitative drug resistance linkage assay that can accurately determine the a ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
Prevention of White Matter Injury in Premature Infants
Amount: $1,693,867.00ABSTRACTUp to 30% of low birth weight preterm infants manifest some form of periventricular white matter injury (PWMI) making it the most common form of brain injury affecting premature infants. PWMI ...
STTRPhase II2020Department of Health and Human Services National Institutes of Health -
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
Amount: $2,978,087.00Project Abstract/Summary Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is a rare disease of mitochondrial energy failure in which the life expectancy of affected children is severely truncate ...
STTRPhase II2020Department of Health and Human Services National Institutes of Health -
Optimization of recombinant probiotics for oral delivery of ACE2/Ang-(1-7
Amount: $225,000.00PROJECT SUMMARYABSTRACT Cardio pulmonary diseases are the leading cause of morbidity and mortality worldwideDespite recent advances in drug therapy and improvements in patient carecardio pulmonary dis ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Prevention of White Matter Injury in Premature Infants
Amount: $223,899.00ABSTRACTUp toof low birth weight preterm infants manifest some form of periventricular white matter injuryPWMImaking it the most common form of brain injury affecting premature infantsPWMI is associat ...
STTRPhase I2019Department of Health and Human Services National Institutes of Health -
Development of a Novel Therapeutic for Hyperthyroidism
Amount: $225,000.00GravesdiseaseGDis the most common cause of hyperthyroidism and is caused by stimulation of the thyroid stimulating hormone receptorTSHRby thyroid receptor stimulating antibodiesTSAbsTreatment of GD in ...
STTRPhase I2019Department of Health and Human Services National Institutes of Health -
Next generation quantitative HCV drug resistance assay
Amount: $232,433.00Project Summary Abstract The objective of this Phase I STTR application is to develop a next generation quantitative drug resistance assay that can accurately determine the abundance and linkage of HC ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Development of CaSR nutrient therapy for childhood diarrhea
Amount: $223,899.00Project Abstract Acute infectious diarrhea is a worldwide problem especially among infants young children and immune compromised patients Sadly million children die each year not because of ...
STTRPhase I2017Department of Health and Human Services National Institutes of Health -
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
Amount: $1,488,962.00Pyruvate dehydrogenase complexPDCdeficiencyPDCDis a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncatedTreatment of PDCD remains a s ...
STTRPhase II2017Department of Health and Human Services National Institutes of Health
